📈 What’s the Market Pricing In for Laurus Labs?

At 95x P/E, the market is betting on a strong long-term transformation: ✅ Shift from a generics API player to a high-margin CDMO platform ✅ Bio-CDMO growth and Vizag fermentation facility as key growth catalysts ✅ Strong earnings recovery with improving margins ✅ China+1 tailwinds driving global CDMO opportunities ✅ Healthy balance sheet with rapid debt reduction The catch? At this valuation, execution has to be near flawless. Any delay in CDMO ramp-up, margin pressure, or continued weakness in the formulations business could lead to a sharp re-rating in the opposite direction. High expectations. High rewards. High risks.